VALGANCICLOVIR TEVA 450 mg, film-coated tablet 60 tablets, CIP 3400930226759
Active ingredients: Valganciclovir hydrochloride, Valganciclovir
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet60 tablets, CIP 3400930226759orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- VALGANCICLOVIR TEVA 450 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 60 plaquette(s) PVC (ACLAR RX) polytrifluorochloroéthylène PVC-Aluminium de 1 comprimé(s)
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 25 Apr 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64913045CIP73022675CIP133400930226759Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| VALGANCICLOVIRcomprimé | 450 mg · un comprimé | FT |
| CHLORHYDRATE DE VALGANCICLOVIRcomprimé | 496,3 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.